Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Rituximab
100%
Open-label Extension
100%
Active Rheumatoid Arthritis
100%
Extension Analysis
100%
European League against Rheumatism (EULAR)
50%
Infection Rate
33%
Adverse Events
33%
American College of Rheumatology
33%
Serious Infection
33%
IgG Levels
33%
ACR50
33%
Lower Limit of Normal
33%
Tumor Necrosis Factor Inhibitor (TNFi)
33%
Double-blind Trial
16%
Rheumatoid Arthritis
16%
Short Form 36 (SF-36)
16%
Safety Concerns
16%
Moderate to Severe
16%
Remission
16%
Previously Treated
16%
Immunoglobulin Levels
16%
Response Criteria
16%
Swollen Joint Count
16%
Best Response
16%
Rheumatoid Arthritis Patients
16%
Tender Joint Count
16%
Chimeric Antibody
16%
Health Assessment Questionnaire
16%
Disability Index
16%
Sustained Clinical Response
16%
Disease Activity Score 28 (DAS28)
16%
Repeated Courses
16%
Nursing and Health Professions
Rheumatoid Arthritis
100%
Rituximab
100%
Inflammatory Arthritis
100%
Efficacy
100%
Accident Prevention
100%
Rheumatic Disease
50%
Infection Rate
33%
Adverse Event
33%
Infusion
33%
Immunoglobulin M
33%
Tumor Necrosis Factor Inhibitor
33%
Remission
16%
Short Form 36
16%
DAS28
16%
Health Assessment Questionnaire
16%
Immunoglobulin Blood Level
16%
Medicine and Dentistry
Rituximab
100%
Rheumatoid Arthritis
100%
Inflammatory Arthritis
100%
Rheumatic Disease
50%
Rheumatology
33%
Infection Rate
33%
Infusion
33%
Immunoglobulin M
33%
TNF Inhibitor
33%
Adverse Event
33%
Short Form 36
16%
Immunoglobulin
16%
Health Assessment Questionnaire
16%
DAS28
16%
Neuroscience
Rituximab
100%
Rheumatoid Arthritis
100%
Rheumatology
33%
Immunoglobulin M
33%
TNF Inhibitor
33%
Intravenous Immunoglobulin
16%